On The Web![[search]](http://wwwcache.wral.com/presentation/v1/images/icons/16x12/search-form-icon.gif){kind=icon}
Site SearchRaleigh, N.C. — Salix Pharmaceuticals (NYSE: SLXP) has acquired a group of drugs from European pharmaceutical firm Dr Falk Pharma for an upfront fee, milestone payments and royalties.
Specific financial terms were not disclosed.
Salix is focused on development and sale of gastrointestinal drugs.
The Dr Falk drugs are already licensed for sale in Europe but have not been approved for use in the United States. The products are sold in the U.K. for treatment of ulcerative colitis, Crohn’s disease and chronic diarrhea due to colitis.
Salix Acquires Rights to Family of Drugs from European Firm
Copyright 2009 by Capitol Broadcasting Company. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
News Alerts to your Email & Cell Phone-
- PC makers may face a legal challenge in ‘Green Dam’ battle from U.S. firm
Jul. 3, 2009 - As Nortel’s final demise nears, what blame should its board shoulder?
Jul. 3, 2009 - Climate change and the economy: Public policies like ‘cap and trade’ and a carbon tax could have big impacts on our wallets.
Jul. 3, 2009 - 20/20: Surgery can let you see like a child again
Jul. 3, 2009 |
- CDC: US swine flu cases rise to nearly 34,000
Jul. 3, 2009
- PC makers may face a legal challenge in ‘Green Dam’ battle from U.S. firm
-
- RTP-based Metabolon raises another $1 million in venture capital
Jul. 2, 2009 - NanoCor Therapeutics raises $2.5M
Jul. 1, 2009 - Despite three IPOs, venture-backed exits drop to trickle in second quarter
Jul. 1, 2009 - Seeking investors? Be sure to find the right angel partners
Jul. 1, 2009 - Georgia Research Alliance venture fund closes on $18.75 million
Jun. 29, 2009
- RTP-based Metabolon raises another $1 million in venture capital
More from wrallocaltechwire.com
Market Watch
advertisement